Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Picks Galderma as Global Partner for Antibody Atopic Dermatitis Drug
Chugai Pharmaceutical has inked a global licensing pact with Swiss-based Galderma Pharma S.A. for its hope-to-be blockbuster nemolizumab, an antibody being developed for the treatment of atopic dermatitis and pruritus in hemodialysis patients, the two companies said on July 21.…
To read the full story
Related Article
- Chugai-Originated Eczema Drug Hits Primary Goal in Japan PIII: Maruho
April 19, 2019
- Galderma Delivers in PIIb Atopic Dermatitis Study for Nemolizumab, Originated by Chugai
March 12, 2019
- Japan PIII for Atopic Dermatitis Drug Nemolizumab to Begin in October: Maruho
September 8, 2017
- Chugai Licenses Atopic Dermatitis Hopeful to Maruho in Japan, Retains Rights for Hemodialysis Pruritus
September 29, 2016
- Chugai Scores Solid Half-Year Sales on Meds for Cancer, Bone and Joint Disease
July 22, 2016
- Sanofi’s Antibody Drug for Atopic Dermatitis Close to Regulatory Filing
June 23, 2016
BUSINESS
- Astellas Tops 2 Trillion Yen in Sales, Gears Up for Post-Xtandi Growth
April 28, 2026
- Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
- Teikoku, Curedisc Ink Japan Deal for Disc Herniation Drug
April 28, 2026
- FRONTEO, Science Tokyo Roll Out AI Drug Discovery Hub
April 28, 2026
- Kyorin to Transfer Generics Unit to Daito-Led JV
April 28, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…